Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2010

View Archived Issues

Memory Pharmaceuticals claims novel 5-HT6 receptor ligands

Novel MIF inhibitors identified by Yale University scientists for cancer therapy

Phase II data support superiority of OvPlex to CA-125 for diagnosis ovarian cancer

Array BioPharma claims novel Pim kinase inhibitors

GlaxoSmithKline presents new interferon inducers

Schering-Plough and Southern Research Institute claim new antivirals

Sirtris Pharmaceuticals presents novel SIRT modulators

Amgen patents novel Na(V)1.7 sodium channel blockers

Cilostazol may benefit patients with acute ischemic stroke

Array Biopharma presents new D2 receptor antagonists for allergic disease

Paricalcitol improves albuminuria in diabetic nephropathy

Eisai and Johns Hopkins to collaborate on development GCPII inhibitors

Xoma initiates phase II trial of XOMA-052 in type 1 diabetes

FDA grants orphan drug status to BioSante's GVAX pancreatic cancer vaccine

Inspire Pharmaceuticals reports phase II data on Azasite for blepharitis

Savient resubmits Krystexxa BLA for chronic gout to FDA

FDA requests additional information regarding Afrezza NDA for hyperglycemia in diabetes

MicuRx files IND for MRX-I antibiotic in China

UCB presents full-year results 2009

Amylin, Lilly and Alkermes receive FDA's complete response letter on once-weekly exenatide

Bio-Path receives FDA approval for clinical evaluation liposomal Grb-2 in cancer

FDA adds boxed warning to Plavix for reduced effectiveness in poor metabolizers of the drug

Revolade approved in Europe for thrombocytopenia in ITP

Orexigen and Patheon enter into exclusive manufacturing agreement for Contrave

Sigma-Aldrich to sell Pfizer's small-molecule compounds to researchers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...